Exploratory study of a KLK2 polymorphism as a prognostic marker in prostate cancer

Cancer Biomarkers

Volumn 7, Issue 2, 2010, Pages 101-108

  Kohli, Manish ^a   Rothberg, Paul G ^b   Feng, Changyong ^b   Messing, Edward ^b   Joseph, Jean ^b   Rao, Sreevidya Sadasiva ^b   Hendershot, Allison ^b   Sahsrabudhe, Deepak ^b  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

kallikrein; polymorphism; prognosis; Prostatic neoplasm

Indexed keywords

CYTOSINE; DNA; KALLIKREIN; PROTEIN KALLIKREIN 2; THYMINE; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ALLELE; ARTICLE; CANCER PATIENT; CANCER RECURRENCE; CANCER RELAPSE; CANCER THERAPY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; EXPLORATORY RESEARCH; GENOTYPE; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; DISEASE-FREE SURVIVAL; GENETIC MARKERS; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROSTATIC NEOPLASMS; RECURRENCE; TISSUE KALLIKREINS;

EID: 78650595744     PISSN: 15740153     EISSN: None     Source Type: Journal    
DOI: 10.3233/CBM-2010-0152     Document Type: Article

References (30)

1. A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu and M.J. Thun, Cancer statistics, CA Cancer J Clin 59 (2009): 225-249.
2. E.S. Antonarakis, A.L. Blackford, E. GarrettMayer and M.A. Eisenberger, Survival in men with nonmetastatic prostate cancer treated with hormone therapy: a quantitative systematic review, J Clin Oncol 25 (2007), 4998-5008.
3. D.P. Petrylak, C.M. Tangen, M.H. Hussain et al., Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer, N Engl J Med 351 (2004), 1513-1520.
4. I.F. Tannock, R. deWit,W.R.Berry et al., Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer, N Engl J Med 351 (2004), 1502-1512.
5. W. Oberaigner, W. Horninger, H. Klocker, D. Schonitzer, W. Stuhlinger and G. Bartsch, Reduction of prostate cancer mortality in Tyrol, Austria, after introduction of prostatespecific antigen testing, Am J Epidemiol 164 (2006), 376-384.
6. J. Concato, C.K. Wells, R.I. Horwitz et al., The effectiveness of screening for prostate cancer: a nested casecontrol study, Arch Intern Med 166 (2006), 38-43.
7. F.H. Schroder, J. Hugosson, M.J. Roobol et al., Screening and prostatecancer mortality in a randomized European study, N Engl J Med 360 (2009), 1320-1328.
8. G.L. Andriole, R.L. Grubb, 3rd, S.S. Buys et al., Mortality results from a randomized prostatecancer screening trial, N Engl J Med 360 (2009), 1310-1319.
9. D.P. Petrylak, D.P. Ankerst, C.S. Jiang et al., Evaluation of prostatespecific antigen declines for surrogacy in patients treated on SWOG 99-16, J Natl Cancer Inst 98 (2006), 516-521.
10. G.M. Yousef and E.P. Diamandis, The new human tissue kallikrein gene family: structure, function, and association to disease, Endocr Rev 22 (2001), 184-204.
11. C. Stephan, K. Jung, M. Lein and E.P. Diamandis, PSA and other tissue kallikreins for prostate cancer detection, Eur J Cancer 43 (2007), 1918-1926.
12. A. Haese, C. Becker, J. Noldus et al., Human glandular kallikrein 2: a potential serum marker for predicting the organ confined versus nonorgan confined growth of prostate cancer, J Urol 163 (2000), 1491-1497.
13. F. Recker, M.K. Kwiatkowski, T. Piironen et al., Human glandular kallikrein as a tool to improve discrimination of poorly differentiated and nonorganconfined prostate cancer compared with prostatespecific antigen, Urology 55 (2000), 481-485.
14. A. Haese, M. Graefen, C. Becker et al., The role of human glandular kallikrein 2 for prediction of pathologically organ confined prostate cancer, Prostate 54 (2003), 181-186.
15. A. Haese, M. Graefen, T. Steuber et al., Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies, J Urol 170 (2003), 2269-2273.
16. A. Haese, M. Graefen, T. Steuber et al., Human glandular kallikrein 2 levels in serum for discrimination of pathologically organconfined from locallyadvanced prostate cancer in total PSAlevels below 10 ng/ml, Prostate 49 (2001), 101-109.
17. R.K. Nam, W.W. Zhang, J. Trachtenberg et al., Single nucleotide polymorphism of the human kallikrein2 gene highly correlates with serum human kallikrein2 levels and in combination enhances prostate cancer detection, J Clin Oncol 21 (2003), 2312-2319.
18. A.O. Crockett and C.T.Wittwer, Fluoresceinlabeled oligonucleotides for realtime pcr: using the inherent quenching of deoxyguanosine nucleotides, Anal Biochem 290 (2001), 89-97.
19. P.G. Rothberg, D. RamirezMontealegre, S.D. Frazier and D.A. Pearce, Homogeneous polymerase chain reaction nucleobase quenching assay to detect the 1kbp deletion in CLN3 that causes Batten disease, J Mol Diagn 6 (2004), 260-263.
20. A.W. Partin, M.W. Kattan, E.N. Subong et al., Combination of prostatespecific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multiinstitutional update, Jama 277 (1997), 1445-1451.
21. A.J. Stephenson, P.T. Scardino, J.A. Eastham et al., Postoperative nomogram predicting the 10year probability of prostate cancer recurrence after radical prostatectomy, J Clin Oncol 23 (2005), 7005-7012.
22. S.J. Freedland, E.B. Humphreys, L.A. Mangold et al., Risk of prostate cancerspecific mortality following biochemical recurrence after radical prostatectomy, Jama 294 (2005), 433-439.
23. G.D. Grossfeld, J.J. Chang, J.M. Broering et al., Under staging and under grading in a contemporary series of patients undergoing radical prostatectomy: Results from the Cancer of the Prostate Strategic Urologic Research Endeavor database, J Urol 165 (2001), 851-856.
24. I.J. Powell, J. Zhou, Y. Sun et al., CYP3A4 genetic variant and diseasefree survival among white and black men after radical prostatectomy, J Urol 172 (2004), 1848-1852.
25. S.S. Strom, Y. Gu, H. Zhang et al., Androgen receptor polymorphisms and risk of biochemical failure among prostatectomy patients, Prostate 60 (2004), 343-351.
26. I.J. Powell, S.J. Land, J. Dey et al., The impact of CAG repeats in exon 1 of the androgen receptor on disease progression after prostatectomy, Cancer 103 (2005), 528-537.
27. A. Shibata, M.I. Garcia, I. Cheng et al., Polymorphisms in the androgen receptor and type II 5 alphareductase genes and prostate cancer prognosis, Prostate 52 (2002), 269-278.
28. J. Lovgren, K. Rajakoski, M. Karp, A. Lundwall and H. Lilja, Activation of the zymogen formof prostatespecific antigen by human glandular kallikrein 2, Biochem Biophys Res Commun 238 (1997), 549-555. (Pubitemid 27464425)
29. C. Stephan, K. Jung, T. Nakamura, G.M. Yousef, G. Kristiansen and E.P.Diamandis, Serumhuman glandular kallikrein 2 (hK2) for distinguishing stage and grade of prostate cancer, Int J Urol 13 (2006), 238-243.
30. A.V. D'Amico, J. Moul, P.R. Carroll, L. Sun, D. Lubeck and M.H. Chen, Cancerspecific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostatespecific antigen era, J Clin Oncol 21 (2003), 2163-2172.